[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643215":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":233,"collaborators":26,"id":236,"slug":237,"hasResults":238,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":26,"eligibilityCriteria":242,"healthyVolunteers":238,"sex":243,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":26,"studyType":249,"phases":250,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":261,"whyStopped":26,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":271},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ZYP group","EXPERIMENTAL","Zishen Yutai Pill, 5g per time, three times daily",[13],"Drug: Zishen Yutai Pill",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Placebo, 5g per time, three times daily",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Zishen Yutai Pill","Eligible participants start to receive ZYP within the first 5 days of their initial menstrual cycle, and will undergo frozen-thawed embryo transfer (FET) in the following cycle. The medication will be taken without interruption till the day of pregnancy test (two weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with negative β-HCG results, the intervention will be stopped.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Eligible participants start to receive placebo within the first 5 days of their initial menstrual cycle, and will undergo frozen-thawed embryo transfer (FET) in the following cycle. The medication will be taken without interruption till the day of pregnancy test (two weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with negative β-HCG results, the intervention will be stopped.",[15],[32],{"name":33,"affiliation":5,"role":34},"Rong Li, MD, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Rong Li","CONTACT","+86 13701085402","roseli001@sina.com",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Xiaoyu Long","+86-010-82264816","doralonger@hotmail.com",[46,64,76,87,102,113,128,143,158,173,188,203,218],{"facility":47,"status":26,"city":48,"state":49,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"The First Affiliated Hospital of University of Science and Technology of China","Hefei","Anhui","China","CN",{"type":53,"coordinates":54},"Point",[55,56],117.28083,31.86389,{"lat":56,"lon":55},[59,63],{"name":60,"role":38,"phone":61,"phoneExt":26,"email":62},"Limin Wu","+86-0551-62283402","wuliminmall@126.com",{"name":60,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":5,"status":26,"city":65,"state":66,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Beijing","Beijing Municipality","100191",{"type":53,"coordinates":69},[70,71],116.39723,39.9075,{"lat":71,"lon":70},[74,75],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":37,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":77,"status":26,"city":65,"state":66,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":78,"geoPoint":80,"contacts":81},"Peking University People's Hospital",{"type":53,"coordinates":79},[70,71],{"lat":71,"lon":70},[82,86],{"name":83,"role":38,"phone":84,"phoneExt":26,"email":85},"Li Tian","+86-010-88324436","Tianli916916@126.com",{"name":83,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":88,"status":26,"city":89,"state":90,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Nanfang Hospital, Southern Medical University","Guangzhou","Guangdong",{"type":53,"coordinates":92},[93,94],113.25,23.11667,{"lat":94,"lon":93},[97,101],{"name":98,"role":38,"phone":99,"phoneExt":26,"email":100},"Yuhua Shi","+86-020-62787614","shiyuhua2003@126.com",{"name":98,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":103,"status":26,"city":89,"state":90,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":104,"geoPoint":106,"contacts":107},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"type":53,"coordinates":105},[93,94],{"lat":94,"lon":93},[108,112],{"name":109,"role":38,"phone":110,"phoneExt":26,"email":111},"Hui Chen","+86-020-81332233","zheling76@163.com",{"name":109,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":114,"status":26,"city":115,"state":116,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"The Second Hospital of Hebei Medical University","Shijiazhuang","Hebei",{"type":53,"coordinates":118},[119,120],114.47861,38.04139,{"lat":120,"lon":119},[123,127],{"name":124,"role":38,"phone":125,"phoneExt":26,"email":126},"Guimin Hao","+86-0311-66002721","Haoguimin@163.com",{"name":124,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":129,"status":26,"city":130,"state":131,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"The Second Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan",{"type":53,"coordinates":133},[134,135],113.64861,34.75778,{"lat":135,"lon":134},[138,142],{"name":139,"role":38,"phone":140,"phoneExt":26,"email":141},"Yungai Xiang","+86-0371-63974718","xiangyungai2063@126.com",{"name":139,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":144,"status":26,"city":145,"state":146,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Xiangya Hospital of Central South University","Changsha","Hunan",{"type":53,"coordinates":148},[149,150],112.97087,28.19874,{"lat":150,"lon":149},[153,157],{"name":154,"role":38,"phone":155,"phoneExt":26,"email":156},"Yanping Li","+86-0731-89752849","lisayanping@sina.com",{"name":154,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":159,"status":26,"city":160,"state":161,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Jiangsu Province Hospital","Nanjing","Jiangsu",{"type":53,"coordinates":163},[164,165],118.77778,32.06167,{"lat":165,"lon":164},[168,172],{"name":169,"role":38,"phone":170,"phoneExt":26,"email":171},"Feiyang Diao","+86-025-68302608","phenix_y@163.com",{"name":169,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":174,"status":26,"city":175,"state":176,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"The First Affiliated Hospital of Xi'an Jiao Tong University","Xi'an","Shaanxi",{"type":53,"coordinates":178},[179,180],108.92861,34.25833,{"lat":180,"lon":179},[183,187],{"name":184,"role":38,"phone":185,"phoneExt":26,"email":186},"Haiyan Wang","+86-029-85323432","bistory@mail.xjtu.edu.cn",{"name":184,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":189,"status":26,"city":190,"state":191,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Shanghai Ninth People's Hospital","Shanghai","Shanghai Municipality",{"type":53,"coordinates":193},[194,195],121.45806,31.22222,{"lat":195,"lon":194},[198,202],{"name":199,"role":38,"phone":200,"phoneExt":26,"email":201},"Qifeng Lv","+86-021-63138341","Lyuqifenf@126.com",{"name":199,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":204,"status":26,"city":205,"state":206,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Sichuan Jinxin Xinan Women and Children's Hospital (Bisheng)","Chengdu","Sichuan",{"type":53,"coordinates":208},[209,210],104.06667,30.66667,{"lat":210,"lon":209},[213,217],{"name":214,"role":38,"phone":215,"phoneExt":26,"email":216},"Xingyu Lv","+86-028-65118868","lxyy323@163.com",{"name":214,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":219,"status":26,"city":220,"state":221,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang",{"type":53,"coordinates":223},[224,225],120.66682,27.99942,{"lat":225,"lon":224},[228,232],{"name":229,"role":38,"phone":230,"phoneExt":26,"email":231},"Haiyan Yang","+86-0577-88069520","13957720491@163.com",{"name":229,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":34,"investigatorFullName":234,"investigatorTitle":235,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Li Rong","Vice President of Peking University Third Hospital, Director of the Department of Reproductive Medicine, Deputy Chair of the Department of Obstetrics and Gynecology, Peking University","100643215","zishen-yutai-pill-for-patients-with-recurrent-implantation-failure-100643215",false,"NCT07641088","Zishen Yutai Pill for Patients With Recurrent Implantation Failure","Zishen Yutai Pill for Patients With Recurrent Implantation Failure: a Randomized, Double-blind, Parallel-group, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for recurrent implantation failure;\n2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \\\u003C43 at enrollment;\n3. Have at least 1 good-quality embryo for transfer;\n4. Intend to undergo frozen-thawed embryo transfer;\n5. Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation;\n2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR);\n3. Thin endometrium (\\\u003C7 mm) before enrollment;\n4. Concomitant severe genital malformations or genital neoplasms;\n5. Contraindications to estrogen and progestogen (e.g., history of breast cancer);\n6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities;\n7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 × the upper limit of normal (ULN), or serum creatinine (Scr) \\> ULN;\n8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and autoimmune diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis);\n9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects;\n10. Allergy to any component of the study drugs;\n11. Participated in another interventional trials within 1 month prior to enrollment;\n12. Deemed unsuitable for this study by the investigator.","FEMALE","20 Years","43 Years",{"count":247,"type":248},878,"ESTIMATED","INTERVENTIONAL",[251],"NA","The goal of this clinical trial is to evaluate the efficacy of Zishen Yutai Pill (ZYP) on pregnancy outcomes following embryo transfer and its safety in patients with recurrent implantation failure. The main question it aims to answer is whether ZYP can improve live birth rate in participant's frozen embryo transfer (FET) cycles.\n\nResearchers will compare ZYP to a placebo (a look-alike substance with similar characteristics to ZYP) to see if it works to improve pregnancy outcomes.\n\nParticipants will:\n\n1. Start to receive ZYP or placebo (5g per time, 3 times daily) within the first 5 days of their initial menstrual cycle, and will undergo FET in the following cycle. The medication will be taken without interruption till the day of pregnancy test (2 weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with a negative β-HCG result, the intervention will be stopped.\n2. Baseline visit will be conducted on days 2-4 of the participant's first menstrual cycle. Subsequent clinic visits will follow the standard protocol for FET cycle, as outlined below:\n\nVisit 1 (days 2-4 of the second menstrual cycle); Visit 2 (day of ovulation or day of endometrial transformation); Visit 3 (day of embryo transfer); Visit 4 (2 weeks after embryo transfer); Visit 5 (5 weeks after embryo transfer). Follow-up is scheduled at 10 weeks after embryo transfer (Visit 6) and after delivery (Visit 7), and these can be conducted remotely.",[254],"Recurrent Implantation Failure",[256,257,258,259,260],"traditional Chinese medicine","Zishen Yutai pill","recurrent implantation failure","frozen-thawed embryo transfer","randomized controlled trial","NOT_YET_RECRUITING","2026-06-10",{"date":264,"type":265},"2026-06-11","ACTUAL",{"date":267,"type":248},"2026-07-01",{"date":269,"type":248},"2029-12-31",{"name":5,"class":6},13]